Takeda Presents Results of Takhzyro (lanadelumab) in P-III HELP Study Open-Label Extension to Treat Hereditary Angioedema Attacks at EAACI 2021
Takeda Exercises its Option with Denali to Co-Develop and Co-Commercialize DNL593 (PTV:PGRN) for Frontotemporal Dementia-Granulin
Shots:
- The P-III HELP OLE study evaluating the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged ≥12yrs. with HAE attacks for ~2.5 yrs.
- Results: 87.4% mean reduction in attack rate compared to baseline & median reduction was 97.7%. Additionally, @70 day steady-state, attack rates were further reduced to a mean of 92.4% & median reduction of 98.2%, 83.7% & 70% patients showed maximum attack-free period after 70 day ≥ 6mos. & ≥ 12mos. respectively
- The therapy was well-tolerated & effectively reduced attack rates over an extended treatment period across subgroups of patients with HAE & safety profile was comparable across all evaluated subgroups with treatment related TEAEs
Click here to read the full press release/ article | Ref: Takeda | Image: Pharmaceutical Technology